Study #2024-0156
EAY191-N5: A randomized trial of Neratinib, a Pan-ERBB inhibitor, alone or in combination with Palbociclib, a CDK4/6 inhibitor, in patients with HER2+ gynecologic cancers and other solid tumors: a ComboMATCH treatment trial
MD Anderson Study Status
Enrolling
Treatment Agent
Neratinib Maleate, Palbociclib
Description
This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
Study phase:
Phase II
Physician name:
Sarina Piha-Paul
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-319-9556
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.